Aptuscan acquired by Avacta

Aptuscan, a spin out company based on research carried out by Paul Ko Ferrigno whilst working at the MRC Cancer Cell Unit, has been acquired by Avacta, an AIM-listed biotechnology company. The acquisition provides strong management to build on the progress that Aptuscan have made with the technology, a critical strategic focus, and new investment.